Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rain Oncology (RAIN)
NASDAQ:RAIN
Holding RAIN?
Track your performance easily
See the Price Targets and Ratings of:
RAIN Analyst Ratings
Hold
0 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RAIN Stock 12 Month Forecast
Average Price Target
$1.39
▲(14.88% Upside)
| Highest Price Target$2.00 | Average Price Target$1.39 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
Reiterated
12/14/23
Mizuho Securities
Reiterated
12/14/23
Oppenheimer
Reiterated
11/10/23
Leerink Partners
Reiterated
11/09/23
Citi
$1
Hold
-17.36%
Downside
Reiterated
09/18/23
Rain Oncology price target lowered to $1 from $1.50 at CitiRain Oncology price target lowered to $1 from $1.50 at Citi
H.C. Wainwright
―
Hold
―
Reiterated
08/11/23
H.C. Wainwright Keeps Their Hold Rating on Rain Therapeutics (RAIN)
EF Hutton
$2
Hold
65.29%
Upside
Reiterated
05/30/23
Analysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (NASDAQ: RAIN), Merck & Company (NYSE: MRK) and Lexicon Pharmaceuticals (NASDAQ: LXRX)
Roth MKM
$1.2
Hold
-0.83%
Downside
Downgraded
05/30/23
Rain Oncology downgraded to Neutral from Buy at Roth MKMRain Oncology downgraded to Neutral from Buy at Roth MKM
Piper Sandler
$1.75
Hold
44.63%
Upside
Downgraded
05/23/23
Rain Oncology downgraded to Neutral from Overweight at Piper SandlerRain Oncology downgraded to Neutral from Overweight at Piper Sandler
RAIN Analyst Recommendation Trends
Rating
Aug 23
Sep 23
Nov 23
Dec 23
Jan 24
Strong Buy
9
0
0
0
0
Buy
1
0
0
0
0
Hold
19
7
9
9
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
7
9
9
9
Each month's total comprises the sum of three months' worth of ratings.
RAIN Financial Forecast
RAIN Stock Forecast FAQ
What is RAIN’s average 12-month price target, according to analysts?
Based on analyst ratings, Rain Oncology’s 12-month average price target is $1.39.
What is RAIN’s upside potential, based on the analysts’ average price target?
Rain Oncology has 14.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RAIN a Buy, Sell or Hold?
Rain Oncology has a consensus rating of Hold which is based on 0 buy ratings, 4 hold ratings and 0 sell ratings.
What is Rain Oncology’s price target?
The average price target for Rain Oncology is $1.39. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.00 ,the lowest forecast is $1.00. The average price target represents 14.88% Increase from the current price of $1.21.
The highest analyst price target is $2.00 ,the lowest forecast is $1.00. The average price target represents 14.88% Increase from the current price of $1.21.
What do analysts say about Rain Oncology?
Rain Oncology’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of RAIN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.